Creo Medical Group PLC
LSE:CREO
Creo Medical Group PLC
LSE:CREO
Price:
36.5 GBX
Market Closed
Updated:
May 21, 2024
P/S
Price to Sales
Price to Sales
4.4
Current
4.1
Median
2.4
Industry
Higher
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=4.4
Market Cap
/
128.1m
Revenue
29.2m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| UK |
|
Creo Medical Group PLC
LSE:CREO
|
128.1m GBP | 4.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
178.5B USD | 4.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
141.5B USD | 19.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD | 3.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
111.7B USD | 7.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.3B USD | 3.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.8B EUR | 2.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
54.3B USD | 8.8 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
51.9B USD | 13.6 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
369.4B CNY | 10.3 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
3.9
2-Years Forward
P/S
3.1
3-Years Forward
P/S
2.4
You don't have any saved screeners yet
